Report overview
Due to the COVID-19 pandemic, the global DT-Based Combined Vaccines market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2023-2030. Fully considering the economic change by this health crisis, the Europe DT-Based Combined Vaccines market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe DT-Based Combined Vaccines landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Protect Against Two or More Diseases accounting for % of the DT-Based Combined Vaccines global market in 2022, is projected to value US$ million by 2030, growing at a revised % CAGR from 2023 to 2030. While Children segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2030.
The global major manufacturers of DT-Based Combined Vaccines include GSK, Changsheng, CCBIO, Aleph Biomedical, Sanofi, Lanzhou Institute Of Biological Product, Siobp, Hualan Bio and Tianyuan Bio-Pharma, etc. In terms of revenue, the global 3 largest players have a % market share of DT-Based Combined Vaccines in 2022.
This report focuses on DT-Based Combined Vaccines volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall DT-Based Combined Vaccines market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global DT-Based Combined Vaccines Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2018 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Protect Against Two or More Diseases
Protect Against One Disease Caused by Different Strains or Serotypes
Segment by Application
Children
Adults
Elderly
Pregnancy
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
GSK
Changsheng
CCBIO
Aleph Biomedical
Sanofi
Lanzhou Institute Of Biological Product
Siobp
Hualan Bio
Tianyuan Bio-Pharma
Vaxtec
Hissen
Abbott
Novartis
Tasly&Jenner
Tiantan
